| Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update KR Crews, A Gaedigk, HM Dunnenberger, JS Leeder, TE Klein, ... Clinical Pharmacology & Therapeutics 95 (4), 376-382, 2014 | 728 | 2014 |
| Inherited NUDT15 Variant Is a Genetic Determinant of Mercaptopurine Intolerance in Children With Acute Lymphoblastic Leukemia JJ Yang, W Landier, W Yang, C Liu, L Hageman, C Cheng, D Pei, Y Chen, ... Journal of clinical oncology 33 (11), 1235-1242, 2015 | 506 | 2015 |
| Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers HM Dunnenberger, KR Crews, JM Hoffman, KE Caudle, U Broeckel, ... Annual review of pharmacology and toxicology 55 (1), 89-106, 2015 | 499 | 2015 |
| Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process KE Caudle, TE Klein, JM Hoffman, DJ Müller, M Whirl-Carrillo, L Gong, ... Current drug metabolism 15 (2), 209, 2014 | 469 | 2014 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype KR Crews, A Gaedigk, HM Dunnenberger, TE Klein, DD Shen, ... Clinical Pharmacology & Therapeutics 91 (2), 321-326, 2012 | 464 | 2012 |
| Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy KR Crews, AA Monte, R Huddart, KE Caudle, ED Kharasch, A Gaedigk, ... Clinical Pharmacology & Therapeutics 110 (4), 888-896, 2021 | 350 | 2021 |
| Pharmacogenomics and individualized medicine: translating science into practice KR Crews, JK Hicks, CH Pui, MV Relling, WE Evans Clinical Pharmacology & Therapeutics 92 (4), 467-475, 2012 | 325 | 2012 |
| Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia B Diouf, KR Crews, G Lew, D Pei, C Cheng, J Bao, JJ Zheng, W Yang, ... Jama 313 (8), 815-823, 2015 | 306 | 2015 |
| PG4KDS: a model for the clinical implementation of pre‐emptive pharmacogenetics JM Hoffman, CE Haidar, MR Wilkinson, KR Crews, DK Baker, ... American Journal of Medical Genetics Part C: Seminars in Medical Genetics …, 2014 | 285 | 2014 |
| Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia G Stocco, MH Cheok, KR Crews, T Dervieux, D French, D Pei, W Yang, ... Clinical Pharmacology & Therapeutics 85 (2), 164-172, 2009 | 271 | 2009 |
| The genomic landscape of pediatric acute lymphoblastic leukemia SW Brady, KG Roberts, Z Gu, L Shi, S Pounds, D Pei, C Cheng, Y Dai, ... Nature genetics 54 (9), 1376-1389, 2022 | 248 | 2022 |
| Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer H Inaba, RB Khan, FH Laningham, KR Crews, CH Pui, NC Daw Annals of oncology 19 (1), 178-184, 2008 | 243 | 2008 |
| Development and use of active clinical decision support for preemptive pharmacogenomics GC Bell, KR Crews, MR Wilkinson, CE Haidar, JK Hicks, DK Baker, ... Journal of the American Medical Informatics Association 21 (e1), e93-e99, 2014 | 240 | 2014 |
| Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia JJ Yang, D Bhojwani, W Yang, X Cai, G Stocco, K Crews, J Wang, ... Blood, The Journal of the American Society of Hematology 112 (10), 4178-4183, 2008 | 238 | 2008 |
| 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study S Bhatia, W Landier, L Hageman, H Kim, Y Chen, KR Crews, WE Evans, ... Blood, The Journal of the American Society of Hematology 124 (15), 2345-2353, 2014 | 215 | 2014 |
| Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group AS Pappo, E Lyden, P Breitfeld, SS Donaldson, E Wiener, D Parham, ... Journal of Clinical Oncology 25 (4), 362-369, 2007 | 207 | 2007 |
| Development and implementation of a pharmacist-managed clinical pharmacogenetics service KR Crews, SJ Cross, JN McCormick, DK Baker, AR Molinelli, R Mullins, ... American Journal of Health-System Pharmacy 68 (2), 143-150, 2011 | 175 | 2011 |
| NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells SW Paugh, EJ Bonten, D Savic, LB Ramsey, WE Thierfelder, P Gurung, ... Nature genetics 47 (6), 607-614, 2015 | 172 | 2015 |
| High‐dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma KR Crews, T Liu, C Rodriguez‐Galindo, M Tan, WH Meyer, JC Panetta, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2004 | 169 | 2004 |
| Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors LM Wagner, KR Crews, LC Iacono, PJ Houghton, CE Fuller, ... Clinical Cancer Research 10 (3), 840-848, 2004 | 155 | 2004 |
Mary V. RellingSt. Jude Children's Research HospitalE-mail megerősítve itt: stjude.org